BackgroundLung cancer is the third most common cancer in the UK with over 47,000 new diagnoses each year. The National Cancer Registration and Analysis Service has quoted that the proportion of patients with non-small cell lung cancer (NSCLC) undergoing surgery each year in the UK was approximately 16% between 2013 and 2015, which represents a marked increase from the 8.8% and 10.6% quoted for 1998 and 2008 respectively (1). Following surgery for lung cancer, the 30-day mortality rate is approximately 2%, and rises to around 5% at 90 days. Oneyear survival after lung cancer surgery is around 88% (2).Reduction of mortality and morbidity after lung cancer surgery is as an important component of improving lung cancer survival. This is because most patients undergoing surgery are early stage (stage I and II) lung cancer patients. Hence, if survival in this group of patients can be optimised, it is likely to have a significant (and disproportionate) impact on overall lung cancer survival rates, because if these patients survive the perioperative period they are much more likely to survive to five years and beyond as compared with patients with more advanced lung cancer.
Complications after thoracic surgeryDevelopment of post-operative complications is associated with poor patient satisfaction (3), prolonged critical care and overall hospital stay, increased healthcare costs and increased mortality. Post-operative complications after thoracic surgery occur in around 15-40% of patients (4). Moreover, the incidence of even a single post-operative complication can lead to additional adverse outcomes (5). Studies looking to reduce rates of complications in this patient group have identified several risk factors associated with complications after thoracic surgery. Interventions aimed at modifying these risk factors could therefore logically lead to better outcomes and improved survival